These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23065705)

  • 1. Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity.
    Yao C; Johnson WM; Gao Y; Wang W; Zhang J; Deak M; Alessi DR; Zhu X; Mieyal JJ; Roder H; Wilson-Delfosse AL; Chen SG
    Hum Mol Genet; 2013 Jan; 22(2):328-44. PubMed ID: 23065705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.
    Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG
    Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
    Liu Z; Hamamichi S; Lee BD; Yang D; Ray A; Caldwell GA; Caldwell KA; Dawson TM; Smith WW; Dawson VL
    Hum Mol Genet; 2011 Oct; 20(20):3933-42. PubMed ID: 21768216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
    Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
    Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redox proteomics analyses of the influence of co-expression of wild-type or mutated LRRK2 and Tau on C. elegans protein expression and oxidative modification: relevance to Parkinson disease.
    Di Domenico F; Sultana R; Ferree A; Smith K; Barone E; Perluigi M; Coccia R; Pierce W; Cai J; Mancuso C; Squillace R; Wiengele M; Dalle-Donne I; Wolozin B; Butterfield DA
    Antioxid Redox Signal; 2012 Dec; 17(11):1490-506. PubMed ID: 22315971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.
    Lee BD; Shin JH; VanKampen J; Petrucelli L; West AB; Ko HS; Lee YI; Maguire-Zeiss KA; Bowers WJ; Federoff HJ; Dawson VL; Dawson TM
    Nat Med; 2010 Sep; 16(9):998-1000. PubMed ID: 20729864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans.
    Saha S; Guillily MD; Ferree A; Lanceta J; Chan D; Ghosh J; Hsu CH; Segal L; Raghavan K; Matsumoto K; Hisamoto N; Kuwahara T; Iwatsubo T; Moore L; Goldstein L; Cookson M; Wolozin B
    J Neurosci; 2009 Jul; 29(29):9210-8. PubMed ID: 19625511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease.
    Johnson WM; Yao C; Siedlak SL; Wang W; Zhu X; Caldwell GA; Wilson-Delfosse AL; Mieyal JJ; Chen SG
    Hum Mol Genet; 2015 Mar; 24(5):1322-35. PubMed ID: 25355420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
    Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
    Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans.
    Yuan Y; Cao P; Smith MA; Kramp K; Huang Y; Hisamoto N; Matsumoto K; Hatzoglou M; Jin H; Feng Z
    PLoS One; 2011; 6(8):e22354. PubMed ID: 21857923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
    Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
    Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration.
    Tsika E; Kannan M; Foo CS; Dikeman D; Glauser L; Gellhaar S; Galter D; Knott GW; Dawson TM; Dawson VL; Moore DJ
    Neurobiol Dis; 2014 Nov; 71():345-58. PubMed ID: 25174890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
    Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
    Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of TIR-1/SARM-1 by miR-71 Protects Dopaminergic Neurons in a
    Naidoo D; de Lencastre A
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating convergent actions of genes linked to familial Parkinson's disease.
    Wolozin B; Saha S; Guillily M; Ferree A; Riley M
    Neurodegener Dis; 2008; 5(3-4):182-5. PubMed ID: 18322385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
    Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
    Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
    Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
    PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.
    Kramer T; Lo Monte F; Göring S; Okala Amombo GM; Schmidt B
    ACS Chem Neurosci; 2012 Mar; 3(3):151-60. PubMed ID: 22860184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.